ITR1 Antibody

What is ITPR1 and what cellular functions does it regulate?

ITPR1 (Inositol 1,4,5-Trisphosphate Receptor Type 1) is a calcium channel receptor protein involved in intracellular calcium homeostasis. It functions as a calcium release channel activated by inositol 1,4,5-trisphosphate (IP3) and plays a crucial role in various cellular processes including neuronal signaling, gene expression, and cell death regulation. ITPR1 is predominantly expressed in the central nervous system, particularly in Purkinje cells of the cerebellum, but is also found in neurons throughout the brain, spinal cord, and peripheral nervous system . When tested by immunohistochemistry on rodent or primate cerebellum sections, ITPR1 antibodies characteristically bind to dendrites and cell bodies of Purkinje cells, creating a distinctive "medusa head" staining pattern .

ITPR1 is encoded by the ITPR1 gene and has a calculated molecular weight of approximately 314 kDa, though it is typically observed at 290-300 kDa in experimental contexts . While primarily considered an intracellular antigen, surface localization of ITPR1 has been reported in certain neurons and other cell types .

What are the primary applications of ITPR1 antibodies in research?

ITPR1 antibodies have multiple validated research applications:

ITPR1 antibodies have been particularly valuable in studying calcium signaling pathways, neuronal function, and in diagnostic applications for autoimmune neurological conditions .

What methods are used for ITPR1 antibody detection in clinical specimens?

The primary method for detecting ITPR1 antibodies in clinical specimens is the Cell-Based Indirect Fluorescent Antibody (CBA-IFA) assay, which utilizes ITPR1-transfected cell lines . This semiquantitative assay is employed for screening and, if positive, is followed by titer determination. The methodology involves:

• Preparation of cells expressing ITPR1 (typically HEK293 cells transfected with murine full-length ITPR1)

• Fixation of cells with acetone on cover glasses, which are then cut into millimeter-sized fragments (biochips)

• Incubation of these biochips with patient serum or CSF samples

• Detection of binding using fluorescently-labeled secondary antibodies (typically FITC-conjugated anti-human IgG)

• Comparison with mock-transfected cells as negative controls

For research applications, validation techniques include Western blot, immunohistochemistry, and flow cytometry, each providing complementary information about antibody specificity and sensitivity .

How should researchers optimize ITPR1 antibody usage in Western blot applications?

For optimal Western blot results with ITPR1 antibodies, researchers should consider the following protocol adaptations:

• Sample preparation: Due to the high molecular weight of ITPR1 (290-300 kDa), use low percentage (6-7%) SDS-PAGE gels and cold transfer conditions to improve large protein transfer efficiency.

• Dilution optimization: Start with a 1:500 dilution of primary antibody and adjust based on signal intensity. Published studies have successfully used dilutions ranging from 1:200 to 1:1000 .

• Positive controls: Include brain tissue lysates (particularly cerebellum) as positive controls, as ITPR1 is highly expressed in these tissues. Mouse brain and liver tissues have been validated as reliable positive controls .

• Detection systems: Use enhanced chemiluminescence (ECL) systems with extended exposure times, as high molecular weight proteins may require longer development times.

• Denaturing conditions: ITPR1 may require modified denaturing conditions; some researchers report improved results when samples are heated at 70°C for 10 minutes rather than 95°C boiling.

• Buffer selection: PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) has been reported as an effective storage buffer for ITPR1 antibodies .

Optimizing these parameters will help ensure specific detection of ITPR1 while minimizing background and non-specific binding.

What considerations are important for experimental design using ITPR1 antibodies?

When designing experiments using ITPR1 antibodies, researchers should address several key considerations:

• Antibody validation: Confirm antibody specificity using multiple methods. For instance, if using polyclonal antibodies, verify target binding using knockout/knockdown controls or peptide blocking experiments.

• Controls selection: Include appropriate controls based on experimental context:

  • Positive controls: Brain tissue for WB/IHC; transfected cells for immunofluorescence

  • Negative controls: Non-expressing tissues or cells

  • For flow cytometry: Consider FMO (Fluorescence Minus One) controls rather than simple isotype controls

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other ITPR isoforms (ITPR2, ITPR3) when studying tissues expressing multiple types.

• Storage and handling: Store antibodies according to manufacturer recommendations (typically -20°C with 50% glycerol). Aliquoting is recommended to avoid freeze-thaw cycles that may affect antibody performance .

• Tissue-specific optimization: When using ITPR1 antibodies for IHC, suggested antigen retrieval with TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 may serve as an alternative .

• Application-specific dilutions: Adjust antibody concentrations based on the specific application:

  • IHC: 1:50-1:500

  • WB: 1:200-1:1000

  • IP: 0.5-4.0 μg for 1.0-3.0 mg total protein lysate

  • Flow cytometry: 0.20 μg per 10^6 cells

How can researchers distinguish between ITPR1 isoforms in experimental systems?

Distinguishing between ITPR1 and other isoforms (ITPR2 and ITPR3) requires careful experimental design:

• Antibody selection: Use antibodies raised against unique epitopes specific to ITPR1 that don't occur in other isoforms. Verify the immunogen sequence used for antibody production to ensure isoform specificity.

• Expression analysis: Compare expression patterns with known tissue distribution profiles:

  • ITPR1: Predominantly expressed in brain (especially cerebellum)

  • ITPR2: Widely expressed, particularly in epithelial tissues

  • ITPR3: Enriched in endocrine and exocrine cells

• Molecular weight differentiation: Though similar in size, slight differences in molecular weight can help differentiate isoforms on Western blots (ITPR1: 290-300 kDa) .

• Knockdown validation: Use siRNA or CRISPR targeting specific isoforms to confirm antibody specificity.

• Recombinant protein controls: Use purified recombinant proteins of each isoform as positive and negative controls.

When absolute specificity is required, combining these approaches provides the most reliable discrimination between ITPR isoforms.

What is the clinical significance of ITPR1 antibodies in neurological disorders?

ITPR1 antibodies have emerged as important biomarkers in neurological disorders, particularly autoimmune conditions affecting the central and peripheral nervous systems. The clinical significance includes:

• Diagnostic value: ITPR1 antibodies are found in a subset of patients with autoimmune cerebellar ataxia, encephalitis, neuropathy, or myelopathy . They serve as important biomarkers that aid in differential diagnosis of these conditions.

• Clinical manifestations: ITPR1 antibody-associated disorders present with diverse neurological symptoms:

  • Cerebellar ataxia (most common)

  • Encephalitis with seizures

  • Cognitive decline and psychosis

  • Peripheral neuropathy

  • Autonomic neuropathy

  • Myelopathy

• Monitoring treatment response: ITPR1 antibody titers may be used to monitor treatment response in antibody-positive individuals .

• Cancer association: ITPR1 antibody disease may be paraneoplastic, with reported associations with breast, lung, and renal cancers . Studies indicate approximately 36-45% of ITPR1 antibody-positive patients have an underlying malignancy , with neurological symptoms often preceding tumor diagnosis.

• Prevalence: Autoantibodies to ITPR1 are relatively rare, detected in approximately 0.015% of neurological patient specimens submitted for paraneoplastic autoantibody evaluation .

• Treatment implications: While immunotherapy response is variable, some patients show improvement with treatments including corticosteroids, plasma exchange, and intravenous immunoglobulins. Long-term treatment with cyclophosphamide has been reported to produce relative stabilization in some cases .

How should clinical testing for ITPR1 antibodies be approached?

Clinical testing for ITPR1 antibodies should follow these methodological guidelines:

• Specimen requirements:

  • Cerebrospinal fluid (CSF) is the preferred specimen type

  • Recommended volume: 0.5 mL CSF (minimum: 0.15 mL)

  • Specimen should be separated and transferred to an appropriate transport tube

  • Avoid grossly hemolyzed or contaminated specimens

• Specimen handling:

  • Ambient: stable for 48 hours

  • Refrigerated: stable for 2 weeks

  • Frozen: stable for 1 month

  • Up to three freeze/thaw cycles are acceptable

• Testing methodology:

  • Cell-Based Indirect Fluorescent Antibody (CBA-IFA) is the recommended method

  • If ITPR1 antibody IgG screening is positive, titer determination should follow

  • Negative results do not rule out autoimmune cerebellar ataxia or related disorders

• Result interpretation:

  • Clinical correlation is essential for interpreting any antineural antibody test

  • Consider testing for other autoantibodies in the differential diagnosis

  • IgG subclass analysis may provide additional insights, as ITPR1-IgG may belong to either IgG1 or IgG2 subclasses

• Follow-up recommendations:

  • Thorough cancer screening is essential when ITPR1 antibodies are detected

  • Regular monitoring with follow-up antibody testing may be valuable for assessing treatment response

What is the relationship between ITPR1 antibodies and paraneoplastic syndromes?

ITPR1 antibodies have a significant association with paraneoplastic neurological syndromes:

• Frequency of cancer association: Studies indicate 36-45% of patients with ITPR1 antibodies have an underlying malignancy .

• Cancer types: Various cancer types have been reported in association with ITPR1 antibodies:

  • Breast cancer (most common)

  • Lung carcinoma

  • Renal cancer

  • Multiple myeloma

  • Endometrial cancer

• Temporal relationship: In most cases, neurological symptoms precede tumor diagnosis, making ITPR1 antibody testing valuable for early cancer detection. In one documented case, neurological symptoms appeared 11 years before cancer diagnosis .

• Tumor expression of ITPR1: Immunopathological studies have demonstrated substantial ITPR1 expression in tumor tissue and metastatic lymph nodes, suggesting a possible mechanism for antibody development through tumor-associated antigen exposure .

• Prognostic implications: ITPR1 may serve as a biomarker of more aggressive tumor behavior, as it has been implicated in cell migration. Some studies suggest ITPR1 upregulation in tumors may protect against natural killer cell cytotoxicity through induction of autophagy .

• Treatment response: In some cases, ITPR1 antibody titers decline after tumor removal, which may correlate with clinical stabilization .

• Screening recommendations: Given the high frequency of malignancy, thorough and ongoing cancer screening is essential when ITPR1 antibodies are detected .

How do researchers address contradictory results in ITPR1 antibody assays?

When confronting contradictory results in ITPR1 antibody assays, researchers should implement the following methodological approach:

• Antibody validation reassessment:

  • Confirm antibody specificity using orthogonal methods (WB, IP, MS)

  • Utilize knockout/knockdown models as negative controls

  • Test multiple antibodies targeting different ITPR1 epitopes

• Technical troubleshooting:

  • Evaluate fixation methods (acetone vs. paraformaldehyde)

  • Assess antigen retrieval protocols (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Optimize antibody concentration through titration experiments

  • Consider detection system sensitivity and specificity

• Biological variability assessment:

  • Account for ITPR1 expression differences across tissues and cell types

  • Consider post-translational modifications affecting epitope accessibility

  • Evaluate sample integrity and protein degradation

  • Assess potential effects of calcium concentration on ITPR1 conformation

• Assay-specific considerations:

  • For CBA, compare results using different transfection systems

  • For WB, evaluate protein extraction methods and denaturing conditions

  • For IHC/IF, compare membrane permeabilization techniques

  • For IP, assess buffer conditions affecting protein-protein interactions

• Reporting recommendations:

  • Document all methodological variables

  • Report negative and conflicting results

  • Include appropriate positive and negative controls

  • Consider multi-laboratory validation for critical findings

What are the latest developments in biophysics-informed modeling for antibody specificity relevant to ITPR1 research?

Recent advances in biophysics-informed modeling for antibody specificity have significant implications for ITPR1 research:

• Integration of high-throughput sequencing and machine learning:

  • Computational approaches now allow predictions beyond experimentally observed sequences

  • These methods enable inference of multiple physical properties not directly measured in experiments

  • Biophysics-informed models can identify and disentangle multiple binding modes associated with specific ligands

• Applications for antibody design:

  • Models can predict and generate specific antibody variants beyond those observed in experiments

  • These approaches enable the design of antibodies with customized specificity profiles

  • Models can be used to create antibodies with either specific high affinity for particular target epitopes or cross-specificity for multiple epitopes

• Experimental validation approaches:

  • Phage display experiments using antibody libraries can be used to train computational models

  • These models can then predict outcomes for new ligand combinations

  • The models demonstrate capacity to propose novel antibody sequences with defined specificity profiles

• Binding mode identification:

  • Computational models can distinguish different binding modes associated with particular ligands

  • This allows discrimination between very similar epitopes, even when these epitopes cannot be experimentally dissociated

  • The approach has particular value when designing antibodies to distinguish between closely related proteins like ITPR isoforms

• Mitigating experimental limitations:

  • These approaches help overcome constraints of experimental selection methods

  • Traditional selection is limited in terms of library size and control over specificity profiles

  • Computational methods provide additional control through high-throughput sequencing and downstream analysis

How can researchers characterize the functional impact of ITPR1 antibodies on calcium signaling?

To characterize the functional impact of ITPR1 antibodies on calcium signaling, researchers can employ several sophisticated methodological approaches:

• Calcium imaging techniques:

  • Use ratiometric calcium indicators (Fura-2, Indo-1) to quantify intracellular calcium concentration changes

  • Apply single-cell calcium imaging to assess cell-to-cell variability in responses

  • Implement calcium oscillation analysis to evaluate temporal dynamics of signaling

• Electrophysiological approaches:

  • Utilize patch-clamp recordings to directly measure ITPR1 channel activity

  • Apply single-channel recordings to assess conductance properties

  • Implement whole-cell recordings to evaluate macroscopic calcium currents

• Cell-based functional assays:

  • Develop reporter cell lines expressing calcium-responsive elements

  • Use CD3ε receptor-specific reporter systems when studying neutralizing potential of antibodies

  • Quantify downstream signaling through luciferase activation or other readouts

• Analysis of channel inhibition mechanisms:

  • Determine if antibodies block the IP3 binding site

  • Assess interference with channel gating

  • Evaluate effects on ITPR1-protein interactions using co-immunoprecipitation

• Experimental design considerations:

  • Pre-incubate cells with antibodies at different ratios to determine dose-dependency

  • Compare effects of antibodies targeting different ITPR1 domains (heavy chain vs. light chain CDRs)

  • Include appropriate controls such as non-specific IgG and domain-specific blocking peptides

• Neutralization assessment:

  • Evaluate inhibition of IP3-induced calcium release

  • Determine EC50 values for functional inhibition

  • Compare effects across different cell types expressing variable levels of ITPR1

What are the emerging applications of ITPR1 antibodies in precision medicine?

ITPR1 antibodies are finding emerging applications in precision medicine approaches, particularly in neurological and oncological contexts:

• Diagnostic stratification:

  • ITPR1 antibody testing enables identification of specific autoimmune neurological syndromes

  • Antibody detection helps distinguish autoimmune from degenerative or vascular etiologies

  • Specific antibody profiles may predict disease course and treatment response

• Cancer detection and monitoring:

  • The high association of ITPR1 antibodies with occult malignancies (36-45%) makes them valuable biomarkers for early cancer detection

  • ITPR1 may serve as a biomarker of aggressive tumor behavior

  • Antibody titers may reflect tumor burden, with declining levels potentially indicating successful treatment

• Treatment selection and monitoring:

  • Antibody characteristics (subclass, titer) may guide immunotherapy approaches

  • IgG subclass analysis provides additional insights - ITPR1-IgG predominantly belongs to IgG2 subclass in some patients, while it is predominantly IgG1 in others with potentially more severe outcomes

  • Persistent antibody detection throughout disease course suggests need for continued immunotherapy

• Neurological syndrome characterization:

  • Beyond classic cerebellar ataxia, ITPR1 antibodies are now associated with broader neurological manifestations:

    • Cognitive decline and memory impairment

    • Psychotic manifestations including hallucinations

    • Limbic encephalitis with temporal lobe hypermetabolism

    • Autonomic dysfunction

    • Seizure disorders

• Research directions and unmet needs:

  • Further studies evaluating ITPR1-IgG frequency in patients with cognitive decline and/or psychosis of unknown etiology

  • Development of standardized assays with improved sensitivity and specificity

  • Investigation of novel immunotherapeutic approaches for ITPR1 antibody-mediated diseases

  • Exploration of the potential pathogenic role of ITPR1 antibodies in neurodegeneration